April 4, 2014
Daiichi Sankyo has announced that it has begun the multinational ENSURE-AF study of its proprietary oral anticoagulant edoxaban, a direct factor Xa-inhibitor, in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion in North America and Europe. In the study,...read more